PDF herunterladen
Horm Metab Res 2021; 53(06): 371-376
DOI: 10.1055/a-1468-4608
Endocrine Care

Outcomes of Patients with Macroprolactinoma Desiring Pregnancy: Follow-Up to 23 Years from a Single Center

Seher Tanrikulu 
1   Istanbul University, Division of Endocrinology and Metabolism, Istanbul, Turkey
2   Istanbul Haydarpaşa Numune Health Training and Research Hospital, Division of Endocrinology and Metabolism, Istanbul, Turkey
,
Sema Yarman
1   Istanbul University, Division of Endocrinology and Metabolism, Istanbul, Turkey
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Macroprolactinomas are rarely seen in women, and pregnancy is a risk factor for tumor growth. More studies are needed to determine appropriate management for macroprolactinoma and pregnancy. The aim of our study is to evaluate effects of treatment with dopamine agonists on macroadenoma before and during pregnancy, safety of dopamine agonists on fetus, post-pregnancy prognosis and long-term results. This is a single center retrospective study. Thirty-four pregnancies occurred in 21 patients under medical therapy. Prolactin levels, treatment results, tumor diameter changes, maternal-fetal outcomes, and disease activity were evaluated. The median tumor size at the time of diagnosis was 15 mm (10–28). Residual adenoma diameter was smaller in those receiving medical therapy longer than one year till the conception (p=0.047). Treatment was discontinued in 28 pregnancies after pregnancy confirmation, and 6 patients were exposed to bromocriptine throughout pregnancy. There was no symptomatic tumor growth during gestation. Among 27 live births, none of the fetuses developed neonatal malformation except for a case of Down syndrome. While early remission rate after pregnancy was 9.5%, this rate reached 33.3% at last follow-up visit. Lowered PRL levels at postpartum period (p=0.040), smaller tumor size at last follow-up visit (p=0.030), and total disappearance of tumor (p=0.026) were the contributor factors for remission. Use of dopamine agonist over one year may reduce the risk of symptomatic tumor growth during pregnancy in patients without invasive or large macroprolactinoma before pregnancy. Exposure to dopamine agonists seems generally safe for the fetus.

Key words

macroprolactinoma - dopamine agonist - pregnancy - fetal outcomes - remission


Publikationsverlauf

Eingereicht: 07. Januar 2021

Angenommen nach Revision: 17. März 2021

Artikel online veröffentlicht:
26. April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Gillam MP, Molitch ME, Lombardi G. et al. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534
    CrossrefPubMedGoogle Scholar
  • 2 Molitch ME. Endocrinology in pregnancy: Management of the pregnant patient with a prolactinoma. Eur J Endocrinol 2015; 172: R205-R213
    CrossrefPubMedGoogle Scholar
  • 3 Araujo B, Belo S, Carvalho D. Pregnancy and tumor outcomes in women with prolactinoma. Exp Clin Endocrinol Diabetes 2017; 125: 642-648
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
    CrossrefPubMedGoogle Scholar
  • 5 Petersenn S, Christ-Crain M, Droste M. et al. Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?. Geburtshilfe Frauenheilkd 2019; 79: 365-374
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 6 Auriemma RS, Perone Y, Di Sarno A. et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 2013; 98: 372-379
    CrossrefPubMedGoogle Scholar
  • 7 Huang W, Molitch ME. Pituitary tumors in pregnancy. Endocrinol Metab Clin North Am 2019; 48: 569-581
    CrossrefPubMedGoogle Scholar
  • 8 Almalki MH, Ur E, Johnson M. et al. Management of prolactinomas during pregnancy – a survey of four Canadian provinces. Clin Invest Med 2012; 35: E96-E104
    CrossrefPubMedGoogle Scholar
  • 9 Colao A, Abs R, Barcena DG. et al. Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008; 68: 66-71
    CrossrefPubMedGoogle Scholar
  • 10 Glezer A, Bronstein MD.Prolactinomas. cabergoline, and pregnancy. Endocrine 2014; 47: 64-69
    CrossrefPubMedGoogle Scholar
  • 11 Lebbe M, Hubinont C, Bernard P. et al. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) 2010; 73: 236-242
    CrossrefPubMedGoogle Scholar
  • 12 Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72: 377-382
    CrossrefPubMedGoogle Scholar
  • 13 Domingue ME, Devuyst F, Alexopoulou O. et al. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf) 2014; 80: 642-648
    CrossrefPubMedGoogle Scholar
  • 14 O'Sullivan SM, Farrant MT, Ogilvie CM. et al. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. Aust N Z J Obstet Gynaecol 2020; 60: 405-411
    CrossrefPubMedGoogle Scholar
  • 15 Ono M, Miki N, Amano K. et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 2010; 95: 2672-2679
    CrossrefPubMedGoogle Scholar
  • 16 Sant' Anna BG, Musolino NRC, Gadelha MR. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary 2020; 23: 120-128
    CrossrefPubMedGoogle Scholar
  • 17 Karaca Z, Yarman S, Ozbas I. et al. How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey. J Endocrinol Invest 2018; 41: 129-141
    CrossrefPubMedGoogle Scholar
  • 18 Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary 2020; 23: 65-69
    CrossrefPubMedGoogle Scholar
  • 19 Holmgren U, Bergstrand G, Hagenfeldt K. et al. Women with prolactinoma–effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol (Copenh) 1986; 111: 452-459
    CrossrefPubMedGoogle Scholar
  • 20 Casanueva FF, Molitch ME, Schlechte JA. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 265-273
    CrossrefPubMedGoogle Scholar
  • 21 Barraud S, Guedra L, Delemer B. et al. Evolution of macroprolactinomas during pregnancy: A cohort study of 85 pregnancies. Clin Endocrinol (Oxf) 2020; 92: 421-427
    CrossrefPubMedGoogle Scholar
  • 22 Yalin GY, Dogansen SC, Yarman S. Review of Clinical Recommendations on Prolactinoma and Pregnancy. Turk J Endocrinol Metab 2018; 22: 54-56
    CrossrefPubMedGoogle Scholar
  • 23 Bigazzi M, Ronga R, Lancranjan I. et al. A pregnancy in an acromegalic woman during bromocriptine treatment: Effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 1979; 48: 9-12
    CrossrefPubMedGoogle Scholar
  • 24 Raymond JP, Goldstein E, Konopka P. et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res 1985; 22: 239-246
    CrossrefPubMedGoogle Scholar
  • 25 Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü TCKBıvTb. Türkiye Nüfus ve Sağlık Araştırması 2018; 160-164
    PubMed
  • 26 Stalldecker G, Mallea-Gil MS, Guitelman M. et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010; 13: 345-350
    CrossrefPubMedGoogle Scholar
  • 27 Canales ES, Garcia IC, Ruiz JE. et al. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 1981; 36: 524-526
    CrossrefPubMedGoogle Scholar
  • 28 Konopka P, Raymond JP, Merceron RE. et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983; 146: 935-938
    CrossrefPubMedGoogle Scholar
  • 29 Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65: 823-827
    CrossrefPubMedGoogle Scholar
  • 30 Rastogi A, Bhadada SK, Bhansali A. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 2017; 33: 270-273
    CrossrefPubMedGoogle Scholar